Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00787033 | A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies | PHASE1 | COMPLETED | 46 | — | — | Dec 1, 2008 | Feb 1, 2012 | Jan 25, 2017 | 5 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dose escalation study with Expansion Cohorts at RP2D and Schedule |
| Name | Type | Description |
|---|---|---|
| PF-04554878 | DRUG | Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging |
Inclusion Criteria: * Patients with advanced non-hematologic malignancies. * Adequate organ function, including bilirubin less than 1.5 x ULN, and ECOG (Eastern Cooperative Oncology Group) performance status of 0-2. Exclusion Criteria: * Clinically significant gastrointestinal abnormalities, requ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |